Eli Lilly and Company (LLY) Set to Launch Oral Obesity Drug in Q2, Reuters Reports

Core Insights - Eli Lilly and Company is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as Q2 2023, pending FDA approval [1][2] - The company has $1.5 billion worth of pre-launch inventory ready for distribution shortly after receiving FDA approval [2] - Eli Lilly has also launched the Employer Connect platform to enhance access to obesity care for employees, facilitating coordination between employers and program administrators [3] Group 1 - Eli Lilly's CFO stated that the FDA review is progressing as expected, and the company remains confident in a decision by Q2 [2] - The company can begin shipping the obesity drug within about a week after FDA approval, enabling a rapid market rollout [2] - The Employer Connect platform aims to close the access gap in U.S. obesity care by providing flexible solutions for employee access to obesity management medications [3] Group 2 - Eli Lilly develops and sells pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [4]